Current and future applications of magnetic resonance imaging (MRI) to breast and ovarian cancer patient management

Puerto Rico Health Sciences Journal

Volumn 29, Issue 3, 2010, Pages 223-231

  Klostergaard, Jim ^a   Parga, Kenia ^b   Raptis, Raphael G ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF PUERTO RICO   (Puerto Rico)

Author keywords

Breast cancer; Contrast agents; Magnetic resonance imaging; Ovarian cancer

Indexed keywords

BREAST TUMOR; FEMALE; FORECASTING; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY TUMOR; REVIEW;

BREAST NEOPLASMS; FEMALE; FORECASTING; HUMANS; MAGNETIC RESONANCE IMAGING; OVARIAN NEOPLASMS;

EID: 77957003253     PISSN: 07380658     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Lehman CD, DeMartini W, Anderson BO, Edge SB. Indications for breast MRI in the patient with newly diagnosed breast cancer. J Natl Compr Canc Netw. 2009 7 (2): 193-201.
2. Schouten van der Velden AP, Boetes C, Bult P, Wobbes T. Magnetic resonance imaging in size assessment of invasive breast carcinoma with an extensive intraductal component. BMC Med Imaging. 2009 7; 9-15.
3. Onesti JK, Mangus BE, Helmer SD, Osland JS. Breast cancer tumor size: correlation between magnetic resonance imaging and pathology measurements. Am J Surg. 2008 196 (6): 844-48; discussion 849-50.
4. Vag T, Baltzer PA, Renz DM, et al. Diagnosis of ductal carcinoma in situ using contrast-enhanced magnetic resonance mammography compared with conventional mammography. Clin Imaging. 2008 32 (6): 438-442.
5. Sardanelli F. Overview of the role of pre-operative breast MRI in the absence of evidence on patient outcomes. Breast. 2010 19 (1): 3-6.
6. Rosen EL, Smith-Foley SA, DeMartini WB, et al. BI-RADS MRI enhancement characteristics of ductal carcinoma in situ. Breast J. 2007 13 (6): 545-550.
7. Raza S, Vallejo M, Chikarmane SA, Birdwell RL. Pure ductal carcinoma in situ: a range of MRI features. AJR Am J Roentgenol. 2008 191 (3): 689-699.
8. Yu J, Park A, Morris E, et al. MRI screening in a clinic population with a family history of breast cancer. Ann Surg Oncol. 2008 15 (2): 452-461.
9. Baltzer PA, Benndorf M, Dietzel M, et al. False-positive findings at contrast-enhanced breast MRI: a BI-RADS descriptor study. AJR Am J Roentgenol. 2010 194 (6): 1658-1663.
10. Mann RM. The effectiveness of MR imaging in the assessment of invasive lobular carcinoma of the breast. Magn Reson Imaging Clin N Am. 2010 18 (2): 259-276, ix.
11. Hollingsworth AB, Stough RG, O'Dell CA, Brekke CE. Breast magnetic resonance imaging for preoperative locoregional staging. Am J Surg. 2008 196 (3): 389-397.
12. Virnig BA, Tuttle TM, Shamliyan T, Kane RL. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst. 2010 102 (3): 170-178.
13. Marcotte-Bloch C, Balu-Maestro C, Chamorey E, et al. MRI for the size assessment of pure ductal carcinoma in situ (DCIS): A prospective study of 33 patients. Eur J Radiol. 2009 (in press).
14. Bloom S, Morrow M. A clinical oncologic perspective on breast magnetic resonance imaging. Magn Reson Imaging Clin N Am. 2010 18 (2): 277- 294, ix.
15. Solin LJ, Orel SG, Hwang WT, Harris EE, Schnall MD. Relationship of breast magnetic resonance imaging to outcome after breast-conservation treatment with radiation for women with early-stage invasive breast carcinoma or ductal carcinoma in situ. J Clin Oncol. 2008 26 (3): 386-391.
16. Solin LJ. Counterview: Pre-operative breast MRI (magnetic resonance imaging) is not recommended for all patients with newly diagnosed breast cancer. Breast. 2010 19 (1): 7-9.
17. Amano G, Yajima M, Moroboshi Y, et al. MRI accurately depicts underlying DCIS in a patient with Paget's disease of the breast without palpable mass and mammography findings. Jpn J Clin Oncol. 2005 35 (3): 149-153.
18. Capobianco G, Spaliviero B, Dessole S, et al. Paget's disease of the nipple diagnosed by MRI. Arch Gynecol Obstet. 2006 274 (5): 316-318.
19. Echevarria JJ, Lopez-Ruiz JA, Martin D, et al. Usefulness of MRI in detecting occult breast cancer associated with Paget's disease of the nippleareolar complex. Br J Radiol. 2004 77 (924): 1036-1039.
20. Frei KA, Bonel HM, Pelte MF, et al. Paget disease of the breast: findings at magnetic resonance imaging and histopathologic correlation. Invest Radiol. 2005 40 (6): 363-367.
21. Haddad N, Ollivier L, Tardivon A, et al. [Usefulness of magnetic resonance imaging in Paget disease of the breast] J Radiol. 2007 88 (4): 579-584.
22. Kim HS, Seok JH, Cha ES, et al. Significance of nipple enhancement of Paget's disease in contrast enhanced breast MRI. Arch Gynecol Obstet. 2009.
23. Morrogh M, Morris EA, Liberman L, et al. MRI identifies otherwise occult disease in select patients with Paget disease of the nipple. J Am Coll Surg. 2008 206 (2): 316-321.
24. Al-Hallaq HA, Mell LK, Bradley JA, et al. Magnetic resonance imaging identifies multifocal and multicentric disease in breast cancer patients who are eligible for partial breast irradiation. Cancer. 2008 113 (9): 2408-2414.
25. Tendulkar RD, Chellman-Jeffers M, Rybicki LA, et al. Preoperative breast magnetic resonance imaging in early breast cancer: implications for partial breast irradiation. Cancer. 2009 115 (8): 1621-1630.
26. Godinez J, Gombos EC, Chikarmane SA, et al. Breast MRI in the evaluation of eligibility for accelerated partial breast irradiation. AJR Am J Roentgenol. 2008 191 (1): 272-277.
27. Straver ME, Loo CE, Rutgers EJ, et al. MRI-model to guide the surgical treatment in breast cancer patients after neoadjuvant chemotherapy. Ann Surg. 2010 251 (4): 701-707.
28. Pengel KE, Loo CE, Teertstra HJ, et al. The impact of preoperative MRI on breast-conserving surgery of invasive cancer: a comparative cohort study. Breast Cancer Res Treat. 2009 116 (1): 161-169.
29. Renz DM, Baltzer PA, Böttcher J, et al. Inflammatory breast carcinoma in magnetic resonance imaging: a comparison with locally advanced breast cancer. Acad Radiol. 2008 15 (2): 209-221.
30. Carbognin G, Calciolari C, Girardi V, et al. Inflammatory breast cancer: MR imaging findings. Radiol Med. 2010 115 (1): 70-82.
31. Le-Petross CH, Bidaut L, Yang WT. Evolving role of imaging modalities in inflammatory breast cancer. Semin Oncol. 2008 35 (1): 51-63.
32. Yang WT, Le-Petross HT, Macapinlac H, et al. Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings. Breast Cancer Res Treat. 2008 109 (3): 417-426.
33. Renz DM, Baltzer PA, Böttcher J, et al. Magnetic resonance imaging of inflammatory breast carcinoma and acute mastitis. A comparative study. Eur Radiol. 2008 18 (11): 2370-2380.
34. Carpenter SG, Stucky CC, Dueck AC, et al. Scientific Presentation Award: The impact of magnetic resonance imaging on surgical treatment of invasive breast cancer. Am J Surg. 2009 198 (4): 475-481.
35. Schouten van der Velden AP, Schlooz-Vries MS, Boetes C, Wobbes T. Magnetic resonance imaging of ductal carcinoma in situ: what is its clinical application? A review. Am J Surg. 2009 198 (2): 262-269.
36. Allen LR, Lago-Toro CE, Hughes JH, et al. Is there a Role for MRI in the Preoperative Assessment of Patients with DCIS? Ann Surg Oncol. 2010 (in press).
37. Houssami, N and Hayes DF. Review of Preoperative Magnetic Resonance Imaging (MRI) in Breast Cancer: Should MRI Be Performed on All Women with Newly Diagnosed, Early Stage Breast Cancer? CA Cancer J Clin 2009; 59: 290-302
38. Turnbull L, Brown S, Harvey I, et al. Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial. The Lancet 2010 375 (9714): 563-571.
39. Turnbull LW. Dynamic contrast-enhanced MRI in the diagnosis and management of breast cancer. NMR Biomed 2009 22: 28-39.
40. Calabrese M, Brizzi D, Carbonaro L et al. Contrast-Enhanced breast MR imaging of claustophobic or oversized patients using an open low-field magnet. Radiol med 2009 114: 267-285.
41. Li J, Yu Y, Zhang Y and Bao S. A clinically feasible method to estimate pharmacokinetic parameters in breast cancer. Am Assoc Phys Med 2009 36 (8): 3786-3794.
42. Galié M, Farace P, Merigo F, et al. Washout of small molecular contrast agent in carcinoma-derived experimental tumors. Microvasc Res 2009 78: 370-378.
43. Craciunescu OI, Blackwell KL, Jones EL, et al. DCE-MRI parameters have potential to predict response of locally advanced breast cancer patients to neoadjuvant chemotherapy and hyperthermia: A pilot study. Int J Hyperthermia 2009 29(6): 405-414.
44. Raatschen HJ, Fu Y, Rogut V, et al. Effects of MRI-Assayed Microvascular Permeability on the Accumulation of Vinorelbine in Xenograft Tumors. Fortschr Röntgenstr 2010 182(2): 133-139.
45. Shaaban A and Revzani MA. Ovarian Cancer: Detection and Radiologic Staging. Clin Obst Gyenocol 2009 52 (1), 73-93.
46. American Cancer Society. What Are the Key Statistics About Ovarian Cancer? Available at: URL: http: //www.cancer.org/docroot/cri/content/ cri_2_4_1x_what_are_the_key_statistics_for_ovarian_cancer_33.asp
47. Twombly R. Cancer killer may be "silent" no more. J Natl Cancer Inst. 2007 99 (18): 1359-1361.
48. Jasen P. From the "silent killer" to the "whispering disease": ovarian cancer and the uses of metaphor. Med Hist. 2009 53 (4): 489-512.
49. Berchuck A, Schildkraut JM, Marks JR, et al. Managing hereditary ovarian cancer risk. Cancer. 1999 86: 2517-2524.
50. Chiaffarino F, Pelucchi C, Parazzini F, et al. Reproductive and hormonal factors and ovarian cancer. Ann Oncol. 2001 12 (3): 337-341.
51. Ebell MH. Estimating the risk of ovarian cancer. Am Fam Physician. 2009 80 (6): 632-634.
52. Chitale R. Monitoring ovarian cancer: CA125 trial stirs controversy. J Natl Cancer Inst. 2009 16; 101 (18): 1233-1235.
53. Walsh CS, Karlan BY. Molecular signatures of ovarian cancer: from detection to prognosis. Mol Diagn Ther. 2010 14 (1): 13-22.
54. Meany DL, Sokoll LJ, Chan DW. Early Detection of Cancer: Immunoassays for Plasma Tumor Markers. Expert Opin Med Diagn. 2009 3 (6): 597-605.
55. Brown DL, Dudiak KM, Laing FC. Adnexal masses: US characterization and reporting. Radiology. 2010 254 (2): 342-354.
56. Dai SY, Hata K, Inubashiri E, et al. Does three-dimensional power Doppler ultrasound improve the diagnostic accuracy for the prediction of adnexal malignancy? J Obstet Gynaecol Res. 2008 34 (3): 364-370.
57. Myers ER, Bastian LA, Havrilesky LJ, et al. Management of adnexal mass. Evid Rep Technol Assess (Full Rep). 2006 130: 1-145. Review.
58. Bhosale P, Iyer R. Diagnostic imaging in gynecologic malignancy. Minerva Ginecol. 2008 60 (2): 143-154. Review.
59. Gjelsteen AC, Ching BH, Meyermann MW, et al. CT, MRI, PET, PET/ CT, and ultrasound in the evaluation of obstetric and gynecologic patients. Surg Clin North Am. 2008 88 (2): 361-390, vii. Review.
60. Ghattamaneni S, Bhuskute NM, Weston MJ, Spencer JA. Discriminative MRI features of fallopian tube masses. Clin Radiol. 2009 64 (8): 815-831. Review.
61. Heilbrun ME, Olpin J, Shaaban A. Imaging of benign adnexal masses: characteristic presentations on ultrasound, computed tomography, and magnetic resonance imaging. Clin Obstet Gynecol. 2009 52 (1): 21-39 Review.
62. Sohaib SA, Mills TD, Sahdev A, et al. The role of magnetic resonance imaging and ultrasound in patients with adnexal masses. Clin Radiol. 2005 60 (3): 340-348.
63. Iyer VR and Lee SI. MRI, CT, and PET/CT for Ovarian Cancer Detection and Adnexal Lesion Characterization. Amer J Roentgen 2010; 194: 311-321. Review
64. Jung SE, Lee JM, Rha SE, Byun JY, Jung JI and Hahn ST. CT and MR imaging of ovarian tumors with emphasis on differential diagnosis. Radiographics 2002 22: 1305-1325.
65. Bent CL, Sahdeva,A, Rockalla AG, et al. MRI appearances of borderline ovarian tumours. Clin Radiol 2009 64 (4): 430-438.
66. Acs G. Serous and mucinous borderline (low malignant potential) tumors of the ovary. Amer Soc Clin Path 2005 123: S13-S57.
67. Low RN, Sebrechts CP, Barone RM and Muller W. Diffusion-Weighted MRI of peritoneal tumors: Comparison with conventional MRI and surgical and histopathologic findings-A feasibility study. Amer J Roentgen 2009 193: 461-470.
68. Fujii S, Matsusue E, Kanasaki Y, et al. Detection of peritoneal dissemination in gynecological malignancy: evaluation by diffusion-weighted MR imaging. Eur Radiol. 2008 18 (1): 18-23.
69. Cormode DP, Jarzyna PA, Mulder WJ and Fayad ZA. Modified natural nanoparticles as contrast agents for medical imaging. Adv Drug Del Rev 2010 62: 329-338.
70. Nune SK, Gunda P, Thallapally PK et al. Nanoparticles for biomedical imaging. Expert Opinion on Drug Delivery 2009 6: 1175-1194.
71. Frangioni JV. New technologies for human cancer imaging. J Clin Oncol 2008 26: 4012-4021.
72. Malancon MP, Lu W and Li C. Nanostructures: Challenges for In Vivo Applications in Cancer Diagnostics and Therapy. MRS Bull 2009 34: 415-421.
73. Lin W, Hyeon T, Lanza GM et al. Magnetic Nanoparticles for Early Detection of Cancer by Magnetic Resonance Imaging. MRS Bull 2009 34: 441-448.
74. Reddy JA, Allagadda VM and Leamon CP. Targeting therapeutic and imaging agents to folate receptor positive tumors. Curr Pharmaceut Biotech 2005 6: 131-150.
75. Cannistra SA, Kansas GS, Niloff J, Defranzo B, Kim Y, Ottensmeier C. Binding of Ovarian-Cancer Cells to Peritoneal Mesothelium in-Vitro Is Partly Mediated by CD44H. Cancer Res 1993; 53: 3830-3838.
76. Neumaier CE, Baio G, Ferrini S et al. MR and iron magnetic nanoparticles. Imaging opportunities in preclinical and translational research. Tumori 2008 94: 226-233.
77. Li X, Du X, Huo T et al. Specific Targeting of Breast Tumor by Octeotride- Conjugated Ultrasmall Superparamagnetic Iron Oxide Particles Using a Clinical 3.0-Tesla Magnetic Resonance Scanner. Acta Radiolog 2009 50(6): 583-594.
78. Chen TJ, Cheng TH, Chen CY et al. Targeted Herceptin-dextran iron oxide nanoparticles for noninvasive imaging of HER2/neu receptors using MRI. J Biol Inorg Chem 2009 14: 253-260.
79. Wang, Z. J.; Boddington, S.; Wendland, M.; Meier, R.; Corot, C.; Daldrup- Link, H. Pediatr Radiol 2008 38(5): 529-537.
80. Meier, R.; Henning, T. D.; Boddington, S.; Tavri, S.; Arora, S.; Piontek, G.; Rudelius, M.; Corot, C.; Daldrup-Link, H. E. Radiol 2010 255(2): 527-535.
81. Xu, H.; Regino, C. A. S.; Koyama, Y.; Hama, Y.; Gunn, A. J.; Bernardo, M.; Kobayashi, H.; Choyke, P. L.; Brechbiel, M. W. Bioconj Chem 2007 18: 1474-1482.